The invention provides a combination of an ancillary agent and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof wherein the ancillary agent is selected from: a monoclonal antibody, an alkylating agent, an anticancer agent, a further CDK inhibitor and a hormone, hormone agonist, hormone antagonist or hormone modulating agent X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring A is a bond, SO2, C=O, NR9(C=O) or 0(C=O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy Y is a bond or an alkylene chain of 1 , 2 or 3 carbon atoms in length R1 is hydrogen a carbocyclic or heterocyclic group having from 3 to 12 ring members or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2 R2 is hydrogen halogen C1-4 alkoxy (e.g. methoxy) or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy) R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).La présente invention concerne une combinaison entre un agent auxiliaire et un composé de formule (0), ou des sels, des tautomères, des N-oxydes ou des solvates dudit composé où ledit agent auxiliaire est sélectionné parmi : un anticorps monoclonal, un agent dalkylation, un agent anticancéreux, un autre inhibiteur de CDK et une hormone, un agoniste dhormone, un antagoniste dhormone ou un agent de régulation dhormone X représente un groupement R1-A-N
